Literature DB >> 28775200

Prognostic Value of 123I-BMIPP SPECT in Patients with Nonischemic Heart Failure with Preserved Ejection Fraction.

Hidenobu Hashimoto1, Rine Nakanishi2, Sunao Mizumura3, Yukiko Hashimoto1, Yuriko Okamura2, Shunsuke Kiuchi2, Junichi Yamazaki2, Takanori Ikeda2.   

Abstract

Imaging of myocardial fatty acid metabolism using 123I-betamethyl-p-iodophenyl-pentadecanoic acid (123I-BMIPP) SPECT is useful for identifying high-risk patients with known ischemic heart disease. However, its utility for patients who have nonischemic heart failure with preserved ejection fraction is not well known. This study aimed to evaluate the prognostic value of the 123I-BMIPP defect score in such patients.
Methods: Of 804 consecutive patients who were admitted to the hospital because of acute heart failure and underwent 123I-BMIPP SPECT, we identified 133 (mean age ± SD, 73 ± 13 y) who had normal coronary arteries by invasive coronary angiography and preserved left ventricular ejection fraction (≥50%) by echocardiography. 123I-BMIPP defects were quantitatively scored to obtain summed defect scores in 17 segments of 123I-BMIPP SPECT images. The patients were divided into 2 groups based on their score. The multivariate Cox model was used to assess a possible correlation between a higher score (≥4, n = 46) and major adverse cardiac events, including cardiac death, cardiovascular events, and hospitalization for heart failure, compared with a lower score (<4, n = 87).
Results: During a mean follow-up of 2.5 y, 35 major adverse cardiac events occurred. The median scores in the high-score and low-score groups were 7.13 ± 4.21 and 1.29 ± 0.80, respectively. By multivariate Cox analysis, a higher score was associated with increased major adverse cardiac events, compared with a lower score (hazard ratio, 11.04; 95% confidence interval, 4.93-24.74; P < 0.001).
Conclusion: This study demonstrated that the defect score by 123I-BMIPP SPECT may have potential prognostic value in patients who have nonischemic heart failure with preserved ejection fraction.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  BMIPP SPECT; major adverse events; nonischemic heart failure with preserved ejection fraction; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28775200     DOI: 10.2967/jnumed.117.195743

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

Review 1.  Myocardial ischemia and coronary disease in heart failure.

Authors:  Beniamino R Pagliaro; Francesco Cannata; Giulio G Stefanini; Leonardo Bolognese
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

2.  Clinical significance of 123I-BMIPP washout rate in patients with uncertain chronic heart failure.

Authors:  Chihiro Aoshima; Shinichiro Fujimoto; Ayako Kudo; Yuko O Kawaguchi; Kazuhisa Takamura; Yuya Matsue; Takao Kato; Yoshifumi Kawamura; Satoshi Kimura; Yuki Kamo; Yui O Nozaki; Daigo Takahashi; Nobuo Tomizawa; Makoto Hiki; Takatoshi Kasai; Shuko Nojiri; Hideyuki Miyauchi; Ken-Ichi Hirano; Kazunori Shimada; Koji Murakami; Tohru Minamino
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-17       Impact factor: 10.057

3.  A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.

Authors:  Shigenori Hiruma; Fumika Shigiyama; Shinji Hisatake; Sunao Mizumura; Nobuyuki Shiraga; Masaaki Hori; Takanori Ikeda; Takahisa Hirose; Naoki Kumashiro
Journal:  Cardiovasc Diabetol       Date:  2021-02-02       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.